~ Dr. Saritha Ravella
Multiple Myeloma (Plasma cell myeloma) is one of my areas of interest in hematological malignancies. It has been an exciting era for Multiple Myeloma with availability of newer targeted therapy options in the treatment of Multiple Myeloma. A newer addition to the armamentarium of therapies now include Carfilzomib (Kyprolis® ).
Carfilzomib is a proteasome inhibitor that is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy. This indication is approved based on improvement in PFS (progression free survival) in a phase 3 trial.